MedTrace Logo

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

NCT06294236 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2025-11-25

No results posted yet for this study

Summary

SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.

Conditions

  • Lupus Erythematosus
  • Systemic Lupus Erythematosus
  • SLE (Systemic Lupus)
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
  • Granulomatous Polyangiitis
  • Microscopic Polyangiitis

Interventions

BIOLOGICAL

SC291

SC291 is an allogeneic CAR T cell therapy

Sponsors & Collaborators

Principal Investigators

  • Kristen Lee · Sana Biotechnology, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2027-12-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06294236 on ClinicalTrials.gov